Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Chaoyuan, Liu"'
Autor:
Yishu Guo, Xianling Liu, Hao Tang, Zhenhua Qiu, Fang Ma, Ao’ran Hu, Chaoyuan Liu, Yapeng Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Pulmonary sarcomatoid carcinoma (PSC) represents a rare and highly aggressive variant of lung cancer, characterized by its recalcitrance to conventional therapeutic modalities and the attendant dismal prognosis it confers. Recent breakthroughs in imm
Externí odkaz:
https://doaj.org/article/a19f11d6c55c4128b6dc46f202851c62
Publikováno v:
JMIR Human Factors, Vol 10, p e46624 (2023)
BackgroundTelemedicine has great potential for diabetes management. The COVID-19 pandemic has boosted the development of telemedicine. However, the factors influencing the behavioral intentions to use and use behaviors of telemedicine in patients wit
Externí odkaz:
https://doaj.org/article/d76eada34b2e474a984d7f232b74b724
Autor:
Chaoyuan Liu, Liang Zeng, Chao Deng, Wenjuan Jiang, Yapeng Wang, Yiguang Zhou, Li Liu, Sisi Wang, Chunhua Zhou, Zhenhua Qiu, Fanxu Zeng, Fang Wu, Jie Weng, Xianling Liu, Nong Yang, Fang Ma
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe combination of a PD-L1 inhibitor plus carboplatin/cisplatin and etoposide (EC/EP) has become a new standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Combining concurrent palliative hypofractionated ra
Externí odkaz:
https://doaj.org/article/1b646bc77d18434a9925070d2c574f1e
Autor:
Mengge Ding, Chao Deng, Xianling Liu, Shun Jiang, Yuan Gao, Dan Fan, Yiguang Zhou, Jiangbo He, Chaoyuan Liu
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain–Barré syndrome (GBS), a rare type
Externí odkaz:
https://doaj.org/article/e3b066387f3b4997b4324858a661da2f
Autor:
Chaoyuan Liu, Wei Zhao, Junpeng Xie, Huashan Lin, Xingsheng Hu, Chang Li, Youlan Shang, Yapeng Wang, Yingjia Jiang, Mengge Ding, Muyun Peng, Tian Xu, Ao’ran Hu, Yuda Huang, Yuan Gao, Xianling Liu, Jun Liu, Fang Ma
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe treatment response to neoadjuvant immunochemotherapy varies among patients with potentially resectable non-small cell lung cancers (NSCLC) and may have severe immune-related adverse effects. We are currently unable to accurately predi
Externí odkaz:
https://doaj.org/article/341afc5556024c33b0b7c03b287a6456
Autor:
Xingsheng Hu, Chunhong Hu, Xianling Liu, Fang Ma, Junpeng Xie, Ping Zhong, Chenxi Tang, Dan Fan, Yuan Gao, Xiang Feng, Mengge Ding, Dezhi Li, Chaoyuan Liu
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundNeoadjuvant chemoimmunotherapy (NCIO) is more effective than neoadjuvant immunotherapy alone for pathological response in non-small cell lung cancer (NSCLC) patients, but the processes for determining patient suitability for its implementat
Externí odkaz:
https://doaj.org/article/9106f94355094cedb1b2d8145efabd79
Autor:
Ao’ran Hu MD, Zui Chen MD, Chaoyuan Liu MD, PhD, Yuan Gao MD, MS, Chao Deng MD, PhD, Xianling Liu MD, PhD
Publikováno v:
Cancer Control, Vol 29 (2022)
Background Small solitary lung cancer (≤2 cm) with extra-thoracic metastasis and no nodal metastasis or intra-thoracic metastasis is a rare situation in clinic. Methods Lung cancer patients with stage T1aN0M0 and T1aN0M1b from 2010 to 2015 were ide
Externí odkaz:
https://doaj.org/article/cb80b02995b9405dba96fc0155dcc71c
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated. Although neoadjuvant-targeted therapy with EGFR-TKI and ALK-TKI showed good
Externí odkaz:
https://doaj.org/article/9ba1a25878c94deaa8e573b87c46bc36
Autor:
Chunhong, Hu, Long, Shu, Chen, Chen, Songqing, Fan, Qingchun, Liang, Hongmei, Zheng, Yue, Pan, Lishu, Zhao, Fangwen, Zou, Chaoyuan, Liu, Wenliang, Liu, Feng-Lei, Yu, Xianling, Liu, Lijuan, Liu, Lingling, Yang, Yang, Shao, Fang, Wu
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Surgery is the standard treatment for patients with stage I non-small cell lung cancer (NSCLC). However, postoperative recurrence leads to a poor prognosis of patients. Currently, there is no effective prognostic biomarker and perioperati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56974109662401aed545b9636dddb96b
https://doi.org/10.21037/tlcr-21-751
https://doi.org/10.21037/tlcr-21-751
BACKGROUND The outbreak of COVID-19 caused a major public health care crisis worldwide On December 7th, 2022, China lifted the “zero tolerance” policy, and the number of patients with COVID-19 infection rose rapidly. Diabetes is a risk factor for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30bfe60a8e209b8e10a0e5a2061da721
https://doi.org/10.2196/preprints.46624
https://doi.org/10.2196/preprints.46624
